Solventum Corp
No enriched coverage for $SOLV in the last 7 days.
No SEC Form 4 filings for $SOLV in the last 30 days.
See all $SOLV insider activity →Solventum’s Q2 outlook is driven by its ERP transition wind-down, planned MedTech portfolio streamlining via a HIS separation, and execution of nearly 20 new product launches by early 2028. Management expects ERP cutover disruptions to subside after Q3. The HIS separation could dilute EPS depending on transaction structure. Solventum shares trade at $82.95.
Mizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
Solventum (NYSE:SOLV) reported Q2 results and said normalized organic sales growth was about 4% excluding ERP timing, SKU rationalization headwinds and a partial separation benefit. MedSurg sales were $1.4B (8.9% organic), Dental $396M (15.2%), HIS $354M (5.4%). Gross margin rose to 60.1% on a $100M tariff refund; EPS was $2.55. The company is advancing a potential HIS separation and raised its 2026 outlook.
Recent SOLV coverage spans earnings, sector analysis and corporate actions.
Near-term volatility risk should fade after Q3 as ERP cutover effects wind down, while HIS separation structure could create EPS dilution or support growth.
The key is post-divestiture capital redeployment and the beat-and-raise setup, which can support near-term estimates.
Raised 2026 outlook and margin guidance, but second-half growth is pressured by advanced-order reversals and separation-related cash demands.
Guidance upside plus a non-core divestiture plan should re-rate the turnaround narrative, with near-term focus on execution and margin/organic growth sustainability.
Earnings beat with modest top-line growth and strong EPS outperformance suggests near-term sentiment support, but flat forward revenue expectations limit upside conviction.
alphai scores every news story that mentions SOLV with an AI model for sentiment and relevance, and aggregates insider trades from Solventum Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Solventum’s Q2 outlook is driven by its ERP transition wind-down, planned MedTech portfolio streamlining via a HIS separation, and execution of nearly 20 new product launches by early 2028. Management expects ERP cutover disruptions to subside after Q3. The HIS separation could dilute EPS depending on transaction structure. Solventum shares trade at $82.95.
3 min readMizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
5 min readSolventum (NYSE:SOLV) reported Q2 results and said normalized organic sales growth was about 4% excluding ERP timing, SKU rationalization headwinds and a partial separation benefit. MedSurg sales were $1.4B (8.9% organic), Dental $396M (15.2%), HIS $354M (5.4%). Gross margin rose to 60.1% on a $100M tariff refund; EPS was $2.55. The company is advancing a potential HIS separation and raised its 2026 outlook.
6 min readSolventum said it will separate its health information systems software business, leaving MedSurg and Dental Solutions, as part of its turnaround. The unit accounted for 16.3% of 2025 sales. Solventum raised 2026 organic sales growth to 2.5% to 3% and adjusted profit per share to $7.10 to $7.20. Q2 adjusted EPS was $2.55 on revenue of $2.21B, beating LSEG estimates.
4 min readSolventum (NYSE:SOLV) reported Q2 CY2026 results with revenue up 2.2% year on year to $2.21 billion, beating market expectations. Non-GAAP EPS was $2.55, 33.8% above analysts’ consensus. The article also cites trailing 12-month sales of $8.31 billion, flat over two years, and Q2 free cash flow of $144 million. Shares rose 3.7% to $90.75.
5 min readSolventum (NYSE: SOLV) reported Q2 2026 sales of $2.2 billion, up 2.2% reported and 9.5% organic. GAAP diluted EPS was $0.53, adjusted $2.55. Operating cash flow was $227 million and free cash flow $144 million. The company said it intends to separate its Health Information Systems segment and raised full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow.
4 min readSolventum Corp (SOLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026-8kerexx991.htm EX-99.1 Document Exhibit 99.1 Solventum Reports Second Quarter 2026 Financial Results • R eported sales increased 2.2%; organic sales increased 9.5% • Announces intent to separate its Health Information Systems business segment • Increases full-yea
6 min readSolventum (SOLV) is set to report Q2 2026 earnings on Aug. 5 after market close. Analysts expect diluted EPS of $1.91, up from $1.69 a year earlier, and full-year EPS of $6.58. The article cites a Moderate Buy consensus and an average $83.67 price target, while noting concerns over weak growth and deteriorating free cash flow margins.
3 min readRenewAtlas and Wiki-Solar report that Indian solar EPC and O&M capacity under development rose 18% year over year, with Larsen & Toubro and Sterling & Wilson among top operators. L&T has 13.2GW across operating and under-development EPC capacity and 70 projects. SECI tendered 1.2GW solar PV plus 600MW/3.6GWh BESS, supporting demand for large ISTS-connected hybrids.
6 min readSolventum Corp (SOLV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. solv-20260716 FALSE 0001964738 0001964738 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported):
2 min read
